These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 11711492)

  • 1. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors upregulate inducible NO synthase expression and activity in vascular smooth muscle cells.
    Kolyada AY; Fedtsov A; Madias NE
    Hypertension; 2001 Nov; 38(5):1024-9. PubMed ID: 11711492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statin treatment upregulates vascular neuronal nitric oxide synthase through Akt/NF-kappaB pathway.
    Nakata S; Tsutsui M; Shimokawa H; Yamashita T; Tanimoto A; Tasaki H; Ozumi K; Sabanai K; Morishita T; Suda O; Hirano H; Sasaguri Y; Nakashima Y; Yanagihara N
    Arterioscler Thromb Vasc Biol; 2007 Jan; 27(1):92-8. PubMed ID: 17082483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atorvastatin inhibition of cytokine-inducible nitric oxide synthase expression in native endothelial cells in situ.
    Wagner AH; Schwabe O; Hecker M
    Br J Pharmacol; 2002 May; 136(1):143-9. PubMed ID: 11976279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells.
    Dichtl W; Dulak J; Frick M; Alber HF; Schwarzacher SP; Ares MP; Nilsson J; Pachinger O; Weidinger F
    Arterioscler Thromb Vasc Biol; 2003 Jan; 23(1):58-63. PubMed ID: 12524225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nitric oxide synthase II (NOS II) gene expression correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoA reductase inhibitors.
    Alfon J; Guasch JF; Berrozpe M; Badimon L
    Atherosclerosis; 1999 Aug; 145(2):325-31. PubMed ID: 10488960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atorvastatin inhibits expression of minichromosome maintenance proteins in vascular smooth muscle cells.
    Bruemmer D; Yin F; Liu J; Kiyono T; Fleck E; Van Herle A; Graf K; Law RE
    Eur J Pharmacol; 2003 Feb; 462(1-3):15-23. PubMed ID: 12591091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3-hydroxy-3-methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvastatin in human endothelial cells.
    Wagner AH; Gebauer M; Güldenzoph B; Hecker M
    Arterioscler Thromb Vasc Biol; 2002 Nov; 22(11):1784-9. PubMed ID: 12426205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells.
    Ortego M; Bustos C; Hernández-Presa MA; Tuñón J; Díaz C; Hernández G; Egido J
    Atherosclerosis; 1999 Dec; 147(2):253-61. PubMed ID: 10559511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular antioxidant effects of atorvastatin in vitro and in vivo.
    Wassmann S; Laufs U; Müller K; Konkol C; Ahlbory K; Bäumer AT; Linz W; Böhm M; Nickenig G
    Arterioscler Thromb Vasc Biol; 2002 Feb; 22(2):300-5. PubMed ID: 11834532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atorvastatin decreases C-reactive protein-induced inflammatory response in pulmonary artery smooth muscle cells by inhibiting nuclear factor-kappaB pathway.
    Li J; Li JJ; He JG; Nan JL; Guo YL; Xiong CM
    Cardiovasc Ther; 2010; 28(1):8-14. PubMed ID: 20074254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-kappaB- and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin.
    Chandrasekar B; Mummidi S; Mahimainathan L; Patel DN; Bailey SR; Imam SZ; Greene WC; Valente AJ
    J Biol Chem; 2006 Jun; 281(22):15099-109. PubMed ID: 16554298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase the binding activity and nuclear level of Oct-1 in mononuclear cells.
    Ortego M; Hernández AG; Bustos C; Blanco-Colio LM; Hernández-Presa MA; Tuñón J; Egido J
    Eur J Pharmacol; 2002 Jul; 448(2-3):113-21. PubMed ID: 12144930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HMG-CoA reductase inhibitor enhances inducible nitric oxide synthase expression in rat vascular smooth muscle cells; involvement of the Rho/Rho kinase pathway.
    Yamamoto T; Takeda K; Harada S; Nakata T; Azuma A; Sasaki S; Nakagawa M
    Atherosclerosis; 2003 Feb; 166(2):213-22. PubMed ID: 12535733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase.
    Wassmann S; Laufs U; Bäumer AT; Müller K; Konkol C; Sauer H; Böhm M; Nickenig G
    Mol Pharmacol; 2001 Mar; 59(3):646-54. PubMed ID: 11179461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance.
    Feron O; Dessy C; Desager JP; Balligand JL
    Circulation; 2001 Jan; 103(1):113-8. PubMed ID: 11136695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HMG-CoA reductase inhibitors inhibit inducible nitric oxide synthase gene expression in macrophages.
    Huang KC; Chen CW; Chen JC; Lin WW
    J Biomed Sci; 2003; 10(4):396-405. PubMed ID: 12824699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells.
    Hernández-Perera O; Pérez-Sala D; Navarro-Antolín J; Sánchez-Pascuala R; Hernández G; Díaz C; Lamas S
    J Clin Invest; 1998 Jun; 101(12):2711-9. PubMed ID: 9637705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation.
    Wagner AH; Köhler T; Rückschloss U; Just I; Hecker M
    Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):61-9. PubMed ID: 10634801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolemic swine independently of their effect on plasma cholesterol levels.
    Martínez-González J; Alfón J; Berrozpe M; Badimon L
    Atherosclerosis; 2001 Nov; 159(1):27-33. PubMed ID: 11689203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors on endothelial nitric oxide synthase and the formation of oxidants in the vasculature.
    Parker RA; Huang Q; Tesfamariam B
    Atherosclerosis; 2003 Jul; 169(1):19-29. PubMed ID: 12860247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.